GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: May 14, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | May 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on May 14, 2025, that it purchased a certain number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing is a Report of Foreign Private Issuer (Form 6-K) for the month of May 2025.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not contain significant new financial or operational information.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker
- May 2025 (date) — Reporting period
- May 14, 2025 (date) — Announcement date
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is acting as GSK's stockbroker for this transaction?
Citigroup Global Markets Limited is acting as GSK's corporate stockbroker.
What is the purpose of this filing?
The purpose is to report a transaction in GSK's own shares.
What is the principal executive office address for GSK plc?
The address is 79 New Oxford Street, London, WC1A 1DG.
Does GSK file annual reports under Form 20-F or 40-F?
GSK indicates it files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 14, 2025 regarding GSK plc (GLAXF).